Navigation Links
NCPA Comments on FTC Action Against CVS Caremark, Vows to Continue PBM Transparency Efforts
Date:1/12/2012

ALEXANDRIA, Va., Jan. 12, 2012 /PRNewswire-USNewswire/ -- The Federal Trade Commission (FTC) announced today that CVS Caremark agreed to pay $5 million to settle allegations that the company overcharged seniors and taxpayers in the Medicare prescription drug program and that the FTC has concluded its investigation into charges alleging that CVS Caremark engaged in anti-consumer, anticompetitive business practices following the 2007 merger of mega-chain CVS with pharmacy benefit manager (PBM) Caremark. The FTC inquiry was launched at the urging of the National Community Pharmacists Association (NCPA) and others.

NCPA CEO B. Douglas Hoey, RPh, MBA issued the following statement in response:

"We appreciate the FTC reviewing the evidence and concerns brought by NCPA, patients, members of Congress and others regarding anti-consumer, anticompetitive behavior by CVS Caremark. The investigation resulted in a multi-million dollar settlement of claims that CVS Caremark overcharged seniors and taxpayers and misled beneficiaries in its marketing of prescription drug plans on Medicare's Plan Finder Website. The settlement should also serve as a warning to any Medicare drug plan sponsors that have potentially misled seniors in their promotion of so-called 'preferred pharmacy' plans.

"At the same time, it is regrettable that the FTC's actions fell short of more robust protections for consumers and pharmacy competition, which are warranted in our view. NCPA provided to the agency what we believe to be compelling evidence, including one-sided contract terms with pharmacy small business owners, patient privacy concerns and a lack of transparency. Now more than ever, NCPA urges Congress and state legislatures to enact legislation, such as S. 1058/H.R. 1971, that provides transparency and promotes pharmacy competition and consumer protections to address these types of questionable practices.

"On behalf of its community pharmacist members and their patients, NCPA opposed the merger of CVS and Caremark from day one. The union of these companies further compounds the inherent, 'the fox is guarding the henhouse' problem with today's prescription drug benefit system. The major PBMs stand virtually alone in the health care sector as self-dealing entities allowed to both provide a health service and manage the reimbursement and other terms of that service for their competitors. Mergers such as CVS Caremark and the pending Express Scripts-Medco arrangement simply pour gasoline on that fire and increase prescription drug costs.

"We appreciate the patients and pharmacists who provided evidence about CVS Caremark's conduct and questionable practices by PBMs. Our efforts concerning CVS Caremark are all part of the ongoing, years-long initiative at NCPA to increase transparency in prescription drug benefit administration and to align the interests of payers, patients, and pharmacists. Those efforts will continue going forward."

The National Community Pharmacists Association (NCPA®) represents the interests of America's community pharmacists, including the owners of more than 23,000 independent community pharmacies. Together they represent a $93 billion health care marketplace, dispense nearly 40% of all retail prescriptions, and employ more than 315,000 people, including 62,400 pharmacists.  Independent community pharmacists are readily accessible medication experts who can help lower health care spending. They are committed to maximizing the appropriate use of lower-cost generic drugs and reducing the estimated $290 billion that is wasted annually by improper medication use. To learn more go to www.ncpanet.org or read NCPA's blog, The Dose, at http://ncpanet.wordpress.com.


'/>"/>
SOURCE National Community Pharmacists Association
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
2. Pediatric Pulmonary Expert Comments on Study of Lung Transplants for Cystic Fibrosis
3. Arpida Provides Further Comments on the Pivotal Phase III Trials
4. SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
5. Arpida Comments on FDAs Anti-infective Drugs Advisory Committee Outcome
6. ACRO Comments on NEJM Article on Globalization of Clinical Research
7. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
8. Endologix Comments on Alleged Patent Infringement
9. AstraZeneca Comments on FDA Joint Advisory Committee Meeting on Post-Marketing Safety Studies for the Use of LABAs in Asthma
10. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
11. Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... DUBLIN , Feb. 17, 2017 ... ("Theravance Biopharma" or the "Company") today announced the ... novel, potent, and orally administered pan-Janus kinase (JAK) ... 12 th Congress of the European Crohn,s ... the Company reported further data from its completed ...
(Date:2/17/2017)... Research and Markets has announced the addition of the "Drug-Eluting ... ... for the US, Canada , Japan ... Latin America , and Rest of World. Annual estimates and ... historic analysis is provided for these markets. Market data and analytics are ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Corrective ... Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. – 3:00 ... corrective action (CA) and preventive action (PA)? , The methods share techniques and ...
(Date:2/17/2017)... ... February 17, 2017 , ... MAP ... today that Karen Pilley has been promoted to Chief Executive Officer. , ... healthcare paradigm – a shift that demands the transition from pay-for-service to pay-for-performance ...
(Date:2/17/2017)... ... ... Like most hospitals across the nation, Onslow Memorial Hospital is looking for more ... Program (HRRP), the return of a patient to the hospital within 30 days of ... providers are struggling to leverage limited resources and technology, Onslow Memorial Hospital has saved ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati ... years of research, development and clinical trials, the founder of Chigurupati Technologies has ... compound of FDA approved ingredients that when infused into alcohol, protect the consumer’s ...
(Date:2/16/2017)... ... February 16, 2017 , ... As a reflection of ... care, NWH has achieved Magnet® recognition for the second time, announced ... The American Nurses Credentialing Center’s Magnet Recognition Program® distinguishes organizations that meet rigorous ...
Breaking Medicine News(10 mins):